Drug class
STAMP inhibitor; allosteric BCR::ABL1 tyrosine kinase inhibitor
Mechanism of action
Binds the myristoyl pocket of the ABL1 kinase domain (STAMP mechanism), allosterically inhibiting BCR::ABL1 kinase activity, including activity of many mutant forms. It acts at a site distinct from the ATP-binding pocket targeted by conventional tyrosine kinase inhibitors.
General use cases
- Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) in adults with product-specific prior-treatment or mutation criteria; consult current US and EMA product information for exact lines of therapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
